Targeting noncoding RNAs to treat atherosclerosis
2024
Преузимање 🢃
Аутори
Sopić, MironVladimirov, Sandra
Munjas, Jelena
Mitić, Tijana
Hall, Ignacio Fernando
Jušić, Amela
Ružić, Dušan
Devaux, Yvan
Чланак у часопису (Објављена верзија)
Метаподаци
Приказ свих података о документуАпстракт
Noncoding RNAs (ncRNAs) are pivotal for various pathological processes, impacting disease progression. The potential for leveraging ncRNAs to prevent or treat atherosclerosis and associated cardiovascular diseases is of great significance, especially given the increasing prevalence of atherosclerosis in an ageing and sedentary population. Together, these diseases impose a substantial socio-economic burden, demanding innovative therapeutic solutions. This review explores the potential of ncRNAs in atherosclerosis treatment. We commence by examining approaches for identifying and characterizing atherosclerosis-associated ncRNAs. We then delve into the functional aspects of ncRNAs in atherosclerosis development and progression. Additionally, we review current RNA and RNA-targeting molecules in development or under approval for clinical use, offering insights into their pharmacological potential. The importance of improved ncRNA delivery strategies is highlighted. Finally, we suggest avenu...es for advanced research to accelerate the use of ncRNAs in treating atherosclerosis and mitigating its societal impact.
Кључне речи:
cardiovascular disease / atherosclerosis / noncoding RNA / RNA / therapeuticsИзвор:
British Journal of Pharmacology, 2024Издавач:
- John Wiley and Sons Inc
Финансирање / пројекти:
- This article is based upon work from COST Action AtheroNET, CA21153 supported by COST (European Cooperation in Science and Technology).
DOI: 10.1111/bph.16412
ISSN: 0007-1188
PubMed: 38720437
WoS: 001215872800001
Scopus: 2-s2.0-85192559641
Институција/група
PharmacyTY - JOUR AU - Sopić, Miron AU - Vladimirov, Sandra AU - Munjas, Jelena AU - Mitić, Tijana AU - Hall, Ignacio Fernando AU - Jušić, Amela AU - Ružić, Dušan AU - Devaux, Yvan PY - 2024 UR - https://farfar.pharmacy.bg.ac.rs/handle/123456789/5637 AB - Noncoding RNAs (ncRNAs) are pivotal for various pathological processes, impacting disease progression. The potential for leveraging ncRNAs to prevent or treat atherosclerosis and associated cardiovascular diseases is of great significance, especially given the increasing prevalence of atherosclerosis in an ageing and sedentary population. Together, these diseases impose a substantial socio-economic burden, demanding innovative therapeutic solutions. This review explores the potential of ncRNAs in atherosclerosis treatment. We commence by examining approaches for identifying and characterizing atherosclerosis-associated ncRNAs. We then delve into the functional aspects of ncRNAs in atherosclerosis development and progression. Additionally, we review current RNA and RNA-targeting molecules in development or under approval for clinical use, offering insights into their pharmacological potential. The importance of improved ncRNA delivery strategies is highlighted. Finally, we suggest avenues for advanced research to accelerate the use of ncRNAs in treating atherosclerosis and mitigating its societal impact. PB - John Wiley and Sons Inc T2 - British Journal of Pharmacology T1 - Targeting noncoding RNAs to treat atherosclerosis DO - 10.1111/bph.16412 ER -
@article{ author = "Sopić, Miron and Vladimirov, Sandra and Munjas, Jelena and Mitić, Tijana and Hall, Ignacio Fernando and Jušić, Amela and Ružić, Dušan and Devaux, Yvan", year = "2024", abstract = "Noncoding RNAs (ncRNAs) are pivotal for various pathological processes, impacting disease progression. The potential for leveraging ncRNAs to prevent or treat atherosclerosis and associated cardiovascular diseases is of great significance, especially given the increasing prevalence of atherosclerosis in an ageing and sedentary population. Together, these diseases impose a substantial socio-economic burden, demanding innovative therapeutic solutions. This review explores the potential of ncRNAs in atherosclerosis treatment. We commence by examining approaches for identifying and characterizing atherosclerosis-associated ncRNAs. We then delve into the functional aspects of ncRNAs in atherosclerosis development and progression. Additionally, we review current RNA and RNA-targeting molecules in development or under approval for clinical use, offering insights into their pharmacological potential. The importance of improved ncRNA delivery strategies is highlighted. Finally, we suggest avenues for advanced research to accelerate the use of ncRNAs in treating atherosclerosis and mitigating its societal impact.", publisher = "John Wiley and Sons Inc", journal = "British Journal of Pharmacology", title = "Targeting noncoding RNAs to treat atherosclerosis", doi = "10.1111/bph.16412" }
Sopić, M., Vladimirov, S., Munjas, J., Mitić, T., Hall, I. F., Jušić, A., Ružić, D.,& Devaux, Y.. (2024). Targeting noncoding RNAs to treat atherosclerosis. in British Journal of Pharmacology John Wiley and Sons Inc.. https://doi.org/10.1111/bph.16412
Sopić M, Vladimirov S, Munjas J, Mitić T, Hall IF, Jušić A, Ružić D, Devaux Y. Targeting noncoding RNAs to treat atherosclerosis. in British Journal of Pharmacology. 2024;. doi:10.1111/bph.16412 .
Sopić, Miron, Vladimirov, Sandra, Munjas, Jelena, Mitić, Tijana, Hall, Ignacio Fernando, Jušić, Amela, Ružić, Dušan, Devaux, Yvan, "Targeting noncoding RNAs to treat atherosclerosis" in British Journal of Pharmacology (2024), https://doi.org/10.1111/bph.16412 . .